Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Abraxane Plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding From VEGF Directed Therapies

NCT00729612 is registered in ClinicalTrials.gov with Greg Otterson as lead sponsor.

NCT NCT00729612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00729612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Abraxane Plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding From VEGF Directed Therapies
Lead sponsor
Greg Otterson
Phase
Phase 2
Overall status
Completed
Start date
August 14, 2008
Completion date
December 16, 2011
Enrollment
63 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer